TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Number of participants with a dose limited toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: GI associated adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients with allelic imbalance at the level of expression of BRCA1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= LLOQ
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in submaximal aerobic exercise capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of tumor recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: drop-out rates
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: number of participants with severe and non severe adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: percentage of participants reporting intervention acceptability scores in highest quartile
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: tai chi class attendance rates
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Survival free of acute cellular rejection and re-transplantation
Endpoint domain: Mortality/survival
Primary endpoint: Symptoms of arthritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: QRS amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Ventricular activation time (VAT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Individuals Completing Informed Consent
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of Individuals Completing the Full Protocol
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Histologically Confirmed Complete Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change for Visual Analog Scale (VAS) on Intensity and annoyance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change for THI Tinnitus Handicap Inventory scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change for TRQ Tinnitus Reaction Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change for STSS Subjective Tinnitus Severity Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Quality of care process index
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Decreased homocysteine level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean medication doses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Δ[HbO2]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Gut Microbiota composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Cmax (maximum concentration of drug in plasma)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentrations of glyburide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentrations of glyburide metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline visual analogue scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change from baseline Oswestry disability index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change from baseline Roland Morris disability questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Incidence of Ocular Discomfort Device-related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Minimal Residual Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Comparison of new PPD to Reference Standard
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Opioid Pain medication use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Non-Opioid pain medication and treatment use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Pain medication use concordant with directions for use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Area Under the Concentration-time Curve of Linagliptin in Plasma Over the Time Interval From 0 to 72 Hours (AUC0-72)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum Measured Concentration of Linagliptin in Plasma (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area Under the Concentration-time Curve of Metformin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cmax of Metformin in Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline on the Non-motor Score of the QWOQ-9
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of patients with efficacy success at 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Left ventricular function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changing perceptions regarding SLT and BQ use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Clinician Erythema Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Reduction in Circulating Tumor Cells (CTCs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence or progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence rate of clinically symptomatic intratumoral hemorrhage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence rate of CNS infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Incidence rate of catheter malfunction
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of treatment non-responders
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of patients improving PaO2/FiO2 ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change from baseline children's psychiatric symptomatology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 10 meters walking test at spontaneous speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence and size of periprocedural myocardial infarction (MI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Performance variables
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Intracranial bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Upper gastrointestinal bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Lower gastrointestinal bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Prostate Volume on Actual MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prostate Volume on US reconstruction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prostate Volume based on US/EM reconstruction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of perioperative hypothermia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With a Herpes Simplex Virus (HSV) Infection
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacokinetic parameters (AUC0-∞, AUC0-t, Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in objective total physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in objective sedentary behaviour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in self-reported total physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glycemic Control using HBA1C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of Thrombosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Intention to become an organ donor
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Frequency of Probiotic Sepsis
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of Blood in Stool
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of Abdominal Distension
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of Emesis
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of disruption in skin integrity in diaper area
Endpoint domain: Adverse events/effects
Primary endpoint: Diagnostic accuracy of PDx mRNA Assay
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of participants who develop a major depressive episode
Endpoint domain: Adverse events/effects
Primary endpoint: Change in depressive symptoms using continuous SCID scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in depressive symptoms using CES-D questionnaire
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in depressive symptoms using PHQ-9 questionnaire
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: complete histological eradication of high grade glandular epithelial neoplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Migraine-Specific Quality of Life Questionnaire-Version 2 (MSQv2) - Role Function Restrictive (RFR) Domain Scores
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change in MSQv2 - Role Function Preventive (RFP) Domain Scores
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change in MSQv2 - Emotional Function (EF) Domain Scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Migraine Disability Assessment Scale (MIDAS) Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Direct cost of GFA compared to myomectomy and UAE
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Rates of acute and near-term serious complications
Endpoint domain: Adverse events/effects
Primary endpoint: Addiction Severity Index Legal Composite
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Area under the plasma concentration versus time curve from single dosing time extrapolated to infinity (AUC0-∞)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration versus time curve from the last time of dosing to the last measurable concentration (AUC0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of atrial tachycardia and atrial fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Concentration of high sensitivity C Reactive Protein (hsCRP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Seropositivity for Group A Streptococcus (GAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Obsessive-compulsive symptom severity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Accuracy of automatic algorithm for fracture reconstruction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Positron Emission Mammography (PEM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Student Adjustment to College
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Pharmacodynamic Changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Immune system outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of treatments for ongoing bleeding episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: 5-month Progression-free Survival (PFS)
Endpoint domain: Mortality/survival
Primary endpoint: Utilization of Long-Acting Reversible Contraceptives (LARC)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Rate of complete exclusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of SANGUINATE™
Endpoint domain: Adverse events/effects
Primary endpoint: Gastric sensitivity to mechanical distention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percent Change in BMI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute Change in Weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change in Fat Mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change in Weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain assessment during intramuscular injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Treatment-emergent Anti-Drug Antibody (ADA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With Neutralizing Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants With At Least One Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Time In Range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Correlation of Peak Displacement (PD) for Detecting Malignancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Weighted Correlation Between Peak Displacement (PD) to Predict Response to Neoadjuvant Chemotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Correlation of Relative Elasticity (RE) for Detecting Malignancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of patients with unreconciled surgical sponge counts
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients requiring an X-ray
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of infants who seroconvert or boost in antibody titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Adverse reaction
Endpoint domain: Adverse events/effects
Primary endpoint: Rates of good/excellent cosmesis
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Methamphetamine subjective effects
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Serum triglyceride response (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma acylated ghrelin response (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: IKDC Score at One Year
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Improvement rates of erosive gastritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Cycling performance on a standardized 40-km time trial course
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Menopause Knowledge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Recurrence of major depressive episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of single dose of CJ-15314
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tmax of single dose of CJ-15314
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUClast of single dose of CJ-15314
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average systolic and diastolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in proportion of senescent cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of pentraxin3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Home Device Measurement Collection Adherence
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Decrease in COPD Assessment Test (CAT) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of Recruitment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Feasibility of Completion
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) Of Inclisiran
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tmax And t1/2 Of Inclisiran
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apparent Total Clearance (CL/F) Following SC Administration Of Inclisiran
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Tumor Response (CR, CCR, PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Bone mineral density (BMD) of the distal femur
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in blood oxidant capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in blood antioxidant capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Absolute and relative changes in peripheral blood mononuclear cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes of immune-related miRNA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in immune response associated gene levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in serum inflammatory cytokines and growth factor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Clinical signs and symptoms of CCU
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Positive and Negative Affect Schedule (PANAS-X)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Capillary pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects with SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of subjects with infusion-related reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of subjects with hypersensitivity reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement in Lip Fullness Scale (LFS2)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Cmax (maximum observed concentration of Telmisartan in plasma)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-72hr (area under the concentration-time curve of Telmisartan in plasma from zero time to 72hr)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to complete closure of Target Ulcer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Success rate of anaesthesia for extraction of maxillary teeth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of modified Rankin Scale of 0 to 2 points
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change From Baseline in MSIS-29 Psychological Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: change in R5-20
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: change in LCI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: change in Scond
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: change in Sacin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in verbal fluency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in language comprehension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cumulative number of Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Time To Recurrence (TTR)
Endpoint domain: Mortality/survival
Primary endpoint: Postendodontic pain rate change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes